Implementation of gastric cancer screening - the global experience.
暂无分享,去创建一个
Mārcis Leja | M. Leja | H. Saito | W. You | M. C. Camargo | Weicheng You | M Constanza Camargo | Hiroshi Saito
[1] I. Choi,et al. Performance of gastric cancer screening by endoscopy testing through the National Cancer Screening Program of Korea , 2011, Cancer science.
[2] P. Malfertheiner,et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED) , 2012, Endoscopy.
[3] T. Chen,et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention , 2012, Gut.
[4] E. Kuipers,et al. Precancerous lesions in the stomach: from biology to clinical patient management. , 2013, Best practice & research. Clinical gastroenterology.
[5] D. Albanes,et al. The relationship between serum ghrelin and the risk of gastric and esophagogastric junctional adenocarcinomas. , 2011, Journal of the National Cancer Institute.
[6] M. Pawlita,et al. A CagA‐independent cluster of antigens related to the risk of noncardia gastric cancer: Associations between Helicobacter pylori antibodies and gastric adenocarcinoma explored by multiplex serology , 2014, International journal of cancer.
[7] X. Shu,et al. Prospective Study of Helicobacter pylori Biomarkers for Gastric Cancer Risk among Chinese Men , 2012, Cancer Epidemiology, Biomarkers & Prevention.
[8] I. Gazeley,et al. Labour and welfare , 2015 .
[9] Pil Je Park,et al. Serum biomarker panels for the diagnosis of gastric adenocarcinoma , 2012, British Journal of Cancer.
[10] Christian O. Bolz,et al. A Novel Line Immunoassay Based on Recombinant Virulence Factors Enables Highly Specific and Sensitive Serologic Diagnosis of Helicobacter pylori Infection , 2013, Clinical and Vaccine Immunology.
[11] K. Miki. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels — “ABC method” , 2011, Proceedings of the Japan Academy. Series B, Physical and biological sciences.
[12] K. Mafune,et al. The Diversity of Gastric Carcinoma , 2005 .
[13] M. Asaka. A new approach for elimination of gastric cancer deaths in Japan , 2013, International journal of cancer.
[14] H. Haick,et al. A nanomaterial-based breath test for distinguishing gastric cancer from benign gastric conditions , 2013, British Journal of Cancer.
[15] P. Moayyedi,et al. Whom should we “test and treat” for Helicobacter pylori? , 2014, BMJ : British Medical Journal.
[16] Y. Yamaji,et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study , 2005, Gut.
[17] K. Fock. Review article: the epidemiology and prevention of gastric cancer , 2014, Alimentary pharmacology & therapeutics.
[18] L. Kupčinskas,et al. Value of gastrin-17 in detecting antral atrophy. , 2011, Advances in medical sciences.
[19] S. Lo,et al. Discovery of diagnostic serum biomarkers of gastric cancer using proteomics , 2008, Proteomics. Clinical applications.
[20] K. Choi,et al. The current status of gastric cancer screening in Korea: report on the National Cancer Screening Programme, 2009. , 2011, Asian Pacific journal of cancer prevention : APJCP.
[21] M. Fujishiro,et al. Cautious comparison between East and West is necessary in terms of the serum pepsinogen test , 2009, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society.
[22] R. Wong,et al. Ethnic Disparities in Gastric Cancer Incidence and Survival in the USA: An Updated Analysis of 1992–2009 SEER Data , 2014, Digestive Diseases and Sciences.
[23] D. Morgan,et al. Gastric cancer incidence and mortality is associated with altitude in the mountainous regions of Pacific Latin America , 2012, Cancer Causes and Control.
[24] T. Nakajima. Historical Review of Research and Treatment of Gastric Cancer in Japan: Clinical Aspect , 2005 .
[25] M. Coleman,et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study. , 2014, The Lancet. Oncology.
[26] Holly Janes,et al. Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design , 2008, Journal of the National Cancer Institute.
[27] C. Abnet,et al. Interleukin-1B Polymorphisms and Gastric Cancer Risk—A Meta-analysis , 2006, Cancer Epidemiology Biomarkers & Prevention.
[28] L. Rosero-Bixby,et al. X-ray screening seems to reduce gastric cancer mortality by half in a community-controlled trial in Costa Rica , 2007, British Journal of Cancer.
[29] E. Fontham,et al. Interleukin-1β and Interleukin-1 Receptor Antagonist Gene Polymorphisms and Gastric Cancer: A Meta-analysis , 2006, Cancer Epidemiology Biomarkers & Prevention.
[30] Wei-Chih Liao,et al. Accuracy of faecal occult blood test and Helicobacter pylori stool antigen test for detection of upper gastrointestinal lesions , 2013, BMJ Open.
[31] M. Asaka,et al. Roadmap to eliminate gastric cancer with Helicobacter pylori eradication and consecutive surveillance in Japan , 2013, Journal of Gastroenterology.
[32] H. Brenner,et al. Gastric Parietal Cell Antibodies, Helicobacter Pylori Infection, and Chronic Atrophic Gastritis: Evidence from a Large Population-based Study in Germany , 2013, Cancer Epidemiology, Biomarkers & Prevention.
[33] T Rokkas,et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report , 2006, Gut.
[34] N. Yoshimura,et al. Cancer High-Risk Subjects Identified by Serum Pepsinogen Tests: Outcomes after 10-Year Follow-up in Asymptomatic Middle-Aged Males , 2008, Cancer Epidemiology Biomarkers & Prevention.
[35] M F Dixon,et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. , 1996, The American journal of surgical pathology.
[36] M. Leja,et al. The effect of incisura angularis biopsy sampling on the assessment of gastritis stage , 2014, European journal of gastroenterology & hepatology.
[37] K. Jørgensen. [Cervix cancer screening]. , 2008, Ugeskrift for laeger.
[38] J. Fraumeni,et al. Serum pepsinogens in relation to precancerous gastric lesions in a population at high risk for gastric cancer. , 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[39] T. Chen,et al. A Community‐Based Study of Helicobacter pylori Therapy Using the Strategy of Test, Treat, Retest, and Re‐treat Initial Treatment Failures , 2006, Helicobacter.
[40] M. Asaka,et al. Design and Planned Analyses of an Ongoing Randomized Trial Assessing the Preventive Effect of Helicobacter pylori Eradication on Occurrence of New Gastric Carcinomas After Endoscopic Resection , 2006, Helicobacter.
[41] K. Choi,et al. Cost-effectiveness outcomes of the national gastric cancer screening program in South Korea. , 2013, Asian Pacific journal of cancer prevention : APJCP.
[42] T. Gotoda,et al. Detection of early gastric cancer: misunderstanding the role of mass screening , 2006, Gastric Cancer.
[43] Jaw-Yuan Wang,et al. Discovery of Tumor Markers for Gastric Cancer by Proteomics , 2014, PloS one.
[44] Gian Franco Gensini,et al. Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report , 2012, Gut.
[45] H. Brenner,et al. Inverse association between a pro-inflammatory genetic profile and Helicobacter pylori seropositivity among patients with chronic atrophic gastritis: enhanced elimination of the infection during disease progression? , 2009, European journal of cancer.
[46] Tomotaka Sobue,et al. The Japanese guidelines for gastric cancer screening. , 2008, Japanese journal of clinical oncology.
[47] M. Pawlita,et al. Helicobacter pylori Multiplex Serology , 2009, Helicobacter.
[48] K. Pan,et al. [Comparison of two gastric cancer screening schemes in a high-risk population]. , 2013, Zhonghua zhong liu za zhi [Chinese journal of oncology].
[49] R. Hunt,et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials , 2014, BMJ : British Medical Journal.
[50] T. Azuma,et al. Prescreening of a High-Risk Group for Gastric Cancer by Serologically Determined Helicobacter pylori Infection and Atrophic Gastritis , 2010, Digestive Diseases and Sciences.
[51] H. Yatsuya,et al. Prospective study of screening for stomach cancer in Japan , 2003, International journal of cancer.
[52] M A Fujino,et al. Accuracy of screening for gastric cancer using serum pepsinogen concentrations , 1999, Gut.
[53] K. Matsuo,et al. Genetic predisposition to Helicobacter pylori-induced gastric precancerous conditions. , 2010, World journal of gastrointestinal oncology.
[54] E. J. Kuipers,et al. Review article: exploring the link between Helicobacter pylori and gastric cancer , 1999, Alimentary pharmacology & therapeutics.
[55] A. Oshima,et al. Evaluation of a mass screening program for stomach cancer with a case‐control study design , 1986, International journal of cancer.
[56] Steven J. M. Jones,et al. Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.
[57] C. Mathers,et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .
[58] M. Kubo,et al. The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study. , 2006, American journal of epidemiology.
[59] M. Chung,et al. The gastric fluid proteome as a potential source of gastric cancer biomarkers. , 2013, Journal of proteomics.
[60] M. Kaminishi,et al. Tests for serum levels of trefoil factor family proteins can improve gastric cancer screening. , 2011, Gastroenterology.
[61] E. Kuipers,et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. , 2008, Gastroenterology.
[62] J. Torres,et al. Biomarkers of Helicobacter pylori-associated gastric cancer , 2013, Gut microbes.
[63] P. Malfertheiner,et al. Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers , 2012, Scandinavian journal of gastroenterology.
[64] M S Pepe,et al. Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.
[65] S. Feig. IARC Handbooks of Cancer Prevention , 2003 .
[66] K. Ulm,et al. Helicobacter pylori antibody responses and evolution of precancerous gastric lesions in a Chinese population , 2014, International journal of cancer.
[67] M. Leja,et al. Gastric cancer: prevention, screening and early diagnosis. , 2014, World journal of gastroenterology.
[68] K. Choi,et al. Gastric Cancer Screening in Korea: Report on the National Cancer Screening Program in 2008 , 2011, Cancer research and treatment : official journal of Korean Cancer Association.
[69] Zhi-gang Huang,et al. Serum trefoil factor 3 is a promising non-invasive biomarker for gastric cancer screening: A monocentric cohort study in China , 2014, BMC Gastroenterology.
[70] Yufei Gao,et al. Urinary metabonomics of stomach cancer assessed by rapid resolution liquid chromatography/time‐of‐flight mass spectrometry , 2013, Chinese medical journal.
[71] P. Malfertheiner,et al. Tumor‐associated autoantibody signature for the early detection of gastric cancer , 2013, International journal of cancer.
[72] A. Jemal,et al. Global Cancer Statistics , 2011 .
[73] T. Kawamoto,et al. Sensitivity and Specificity of Mass Screening for Gastric Cancer Using the Measurement of Serum Pepsinogens , 1995, Japanese journal of cancer research : Gann.
[74] M. Gail,et al. Detection of gastric carcinoma‐associated MG7‐Ag by serum immuno‐PCR assay in a high‐risk Chinese population, with implication for screening , 2010, International journal of cancer.
[75] C. la Vecchia,et al. Association Between Cytokine Gene Polymorphisms and Gastric Precancerous Lesions: Systematic Review and Meta-analysis , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[76] W. Blot,et al. Precancerous gastric lesions in a population at high risk of stomach cancer. , 1993, Cancer research.
[77] I. Tsuji,et al. The evaluation of screening for gastric cancer in miyagi prefecture, Japan: A population‐based case‐control study , 1995, International journal of cancer.
[78] M. Dinis-Ribeiro,et al. Screening for Gastric Cancer and Surveillance of Premalignant Lesions: a Systematic Review of Cost‐Effectiveness Studies , 2013, Helicobacter.
[79] Qiaojia Huang,et al. Identification of transgelin as a potential novel biomarker for gastric adenocarcinoma based on proteomics technology , 2008, Journal of Cancer Research and Clinical Oncology.
[80] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[81] D. Forman,et al. Helicobacter pylori Eradication in the Prevention of Gastric Cancer: Are More Trials Needed? , 2013, Current Oncology Reports.
[82] L. Kupčinskas,et al. The Validity of a Biomarker Method for Indirect Detection of Gastric Mucosal Atrophy Versus Standard Histopathology , 2009, Digestive Diseases and Sciences.
[83] I. Lansdorp-Vogelaar,et al. Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention. , 2013, Best practice & research. Clinical gastroenterology.
[84] Manami Inoue,et al. Gastric cancer screening and subsequent risk of gastric cancer: A large‐scale population‐based cohort study, with a 13‐year follow‐up in Japan , 2006, International journal of cancer.
[85] Yoshiyuki Watanabe,et al. Validation of the pepsinogen test method for gastric cancer screening using a follow-up study , 2009, Gastric Cancer.
[86] P. Malfertheiner,et al. Macro-Role of MicroRNA in Gastric Cancer , 2012, Digestive Diseases.
[87] M. Loh,et al. Clinical Potential of DNA Methylation in Gastric Cancer: A Meta-Analysis , 2012, PloS one.